scholarly journals Comparison of Calcaneal Taping and Low-Dye Taping for the Short-Term Management of Plantar Fasciitis

2021 ◽  
Vol 06 (04) ◽  
pp. 19-25
Author(s):  
Kalpana Zutshi ◽  
Keyword(s):  
Plantar Fasciitis ◽  
Conventional Treatment ◽  
Therapeutic Option ◽  
Term Treatment ◽  
Treatment Result ◽  
Short Term ◽  
Short Term Treatment ◽  
Passive Stretching ◽  
Significant Difference ◽  
Term Management

Background: Plantar fasciitis is one of the most common causes of heel and foot pain. Physical therapists have applied many techniques in an attempt to relieve the symptoms of plantar fasciitis, including various taping methods for which there is little existing evidence. Purpose of the study is to compare the effects of 2 different taping techniques in short-term management of plantar fasciitis. Study design was randomized pre- and post-test different subject experimental design. Methods and Measure: Subjects (n=30) were randomly assigned into 3 groups: (A) calcaneal taping and conventional treatment,(B) low-dye taping and conventional treatment, (C) conventional treatment only. Visual analog scale (VAS) for first-step pain and foot function index scale (FFI) for functional activities were measured pretreatment, 4th day and after 1 week of treatment, 7th day ( post-treatment). Result: Follow up analysis revealed that calcaneal and low-dye taping showed greater improvement on 2nd and 3rd session compared to conventional treatment. Conclusion: Subjects treated with calcaneal and low-dye taping along with ultrasound and passive stretching showed an additional and more significant improvement as compared to ultrasound and passive stretching only and also there was no significant difference found between calcaneal and low-dye taping groups in terms of reduction of pain on VAS and FFI. Hence, it can be concluded that both calcaneal and low-dye taping techniques are effective therapeutic option in short-term treatment of plantar fasciitis.

Effects of Short-term Treatment with Kinesiotaping for Plantar Fasciitis

2010 ◽  
Vol 18 (1) ◽  
pp. 71-80 ◽  
Author(s):  
Chien-Tsung Tsai ◽  
Wen-Dien Chang ◽  
Jen-Pei Lee
Keyword(s):  
Plantar Fasciitis ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

Effectiveness of Low-Dye Taping for the Short-term Management of Plantar Fasciitis

2005 ◽  
Vol 95 (6) ◽  
pp. 525-530 ◽  
Author(s):  
Karl B. Landorf ◽  
Joel A. Radford ◽  
Anne-Maree Keenan ◽  
Anthony C. Redmond
Keyword(s):  
Therapeutic Effect ◽  
Plantar Fasciitis ◽  
Pain Scale ◽  
Term Treatment ◽  
Analysis Of Covariance ◽  
Control Group ◽  
Visual Analog Pain Scale ◽  
Short Term ◽  
Short Term Treatment ◽  
Intention To Treat

Low-Dye taping is often used as a short-term treatment for plantar fasciitis. We evaluated the short-term effectiveness of low-Dye taping in relieving pain associated with plantar fasciitis. In this comparative study conducted at a university-based clinic, 65 participants with plantar fasciitis who received low-Dye taping for 3 to 5 days were compared with 40 participants who did not receive taping. Pain before and after treatment was measured using a visual analog pain scale. Analysis of the data was by the intention-to-treat principle, and a linear regression approach to analysis of covariance was used to compare effects. The visual analog pain scale score improved by a mean of 20 mm (from 44 to 24 mm) in the taping group and worsened by a mean of 6 mm (from 51 to 57 mm) in the control group. The analysis of covariance–adjusted difference in therapeutic effect favored the taping group by 31.7 mm (95% confidence interval, 23.6–39.9 mm) and was statistically significant (t = 7.71). In the short term, low-Dye taping significantly reduces the pain associated with plantar fasciitis. These findings are the first quantitative results to demonstrate the significant therapeutic effect of this treatment modality in relieving the symptoms associated with plantar fasciitis. (J Am Podiatr Med Assoc 95(6): 525–530, 2005)

A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression

2002 ◽  
Vol 17 (S3) ◽  
pp. 331s-340s ◽  
Author(s):  
S. Kasper ◽  
J.P. Olié
Keyword(s):  
Selective Serotonin Reuptake Inhibitors ◽  
Rating Scale ◽  
Meta Analysis ◽  
Therapeutic Index ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Treatment Groups ◽  
Treatment Of Depression ◽  
Significant Difference

SummaryA meta-analysis was performed to compare the efficacy of tianeptine and selective serotonin reuptake inhibitors (SSRI) in the short-term treatment of depression. Consecutive selection and inclusion processes allowed five studies to be selected: two studies on tianeptine versus fluoxetine, two studies on tianeptine versus paroxetine, and one study on tianeptine versus sertraline. A total of 1348 patients were included in the five studies; 681 subjects received an SSRI and 667 tianeptine.A strict step-by-step methodology was applied in order to legitimize this meta-analysis and to interpret the results. Considering all the patients or those with a Montgomery–Åsberg Depression Rating Scale (MADRS) inclusion score greater than 28, none of the assessed parameters (MADRS total score and responder rate) revealed any significant difference between the two treatment groups. Further analysis based on clinical global impression (CGI) items found no significant difference, except for CGI item 3 (therapeutic index), where a tendency (P=0.06 or 0.07 depending on the methodology) was found in favor of tianeptine. All in all, this study confirmed that tianeptine is at least as effective as SSRI, with a trend for a better acceptability profile in the treatment of depressed patients.

scholarly journals Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Juan Li ◽  
Chunhua Hu ◽  
Yi Chen ◽  
Rou Zhang ◽  
Shan Fu ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Term Treatment ◽  
Efficacy And Safety ◽  
Short Term ◽  
Serum Cystatin C ◽  
Short Term Treatment ◽  
Link Type ◽  
Long Term Treatment ◽  
Significant Difference

Abstract Background & Aims There is limited evidence on the efficacy and safety of nucleos(t) ide analogues (NAs) in the treatment of HBV-ACLF. Our objective was to evaluate the outcomes among TAF, TDF and ETV, three first-line antivirals against chronic hepatitis B, in patients with HBV-ACLF. Methods Patients with HBV-related ACLF were recruited and received daily TAF (25 mg/d), TDF (300 mg/d) and ETV (0.5 mg/d). They were prospectively followed-up. The primary endpoint was overall survival at week 12 and week 48, the secondary endpoints were virological response and biochemical response. Results Forty gender and age matched eligible subjects were recruited and divided into three groups: TAF group, TDF group and ETV group. By week 48, 8 (80%) patients in TAF group, 6 (60%) patients in TDF group and 17 (85%) patients in ETV group survived without liver transplantation (P = 0.251). After 4 weeks of NAs treatment, all three groups showed paralleling reduction of HBV DNA levels. All three groups presented similar biochemical responses at week 4, patients treated with TAF showed a priority in total bilirubin reduction, albumin and cholesterol maintenance. Additionally, although there was no significant difference in changes of serum urea, serum creatinine, serum cystatin C and estimated GFR among the three groups by treatment week 4, TDF showed unfavorable renal safety even in short -term treatment. The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported. Conclusions TAF, TDF and ETV are of similar efficacy and safety in short-term and long-term treatment of HBV-ACLF. Trial registration This study is ongoing and is registered with ClinicalTrials.gov, NCT03640728 (05/02/2019).

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute‐on‐chronic liver failure associated with hepatitis B

2021 ◽  
Author(s):  
Juan Li ◽  
Chunhua Hu ◽  
Yi Chen ◽  
Rou Zhang ◽  
Shan Fu ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Similar Efficacy ◽  
Term Treatment ◽  
Efficacy And Safety ◽  
Short Term ◽  
Serum Cystatin C ◽  
Short Term Treatment ◽  
Long Term Treatment ◽  
Significant Difference

Abstract Background & Aims: There is limited evidence on the efficacy and safety of nucleos(t)ide analogues (NAs) in the treatment of HBV-ACLF. Our objective was to evaluate the outcomes among TAF, TDF and ETV, three first-line antivirals against chronic hepatitis B, in patients with HBV-ACLF. Methods: Patients with HBV-related ACLF were recruited and received daily TAF (25mg/d), TDF (300 mg/d) and ETV (0.5 mg/d). They were prospectively followed-up. The primary endpoint was overall survival at week 12 and week 48, the secondary endpoints were virological response and biochemical response. Results: Forty gender and age matched eligible subjects were recruited and divided into three groups: TAF group, TDF group and ETV group. By week 48, 8 (80%) patients in TAF group, 6 (60%) patients in TDF group and 17 (85%) patients in ETV group survived without liver transplantation (P = 0.251). After 4 weeks of NAs treatment, all three groups showed paralleling reduction of HBV DNA levels. All three groups presented similar biochemical responses at week 4, patients treated with TAF showed a priority in total bilirubin reduction, albumin and cholesterol maintenance. Additionally, although there was no significant difference in changes of serum urea, serum creatinine, serum cystatin C and estimated GFR among the three groups by treatment week 4, TDF showed unfavorable renal safety even in short term treatment. The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported. Conclusions: TAF, TDF and ETV are of similar efficacy and safety in short-term and long-term treatment of HBV-ACLF. This study is ongoing and is registered with ClinicalTrials.gov, NCT03640728 (05/02/2019).

scholarly journals Effectiveness of Taping for the Short-Term Treatment of Pain and Walking Speed in Patients with Plantar Fasciitis

1970 ◽  
Vol 5 (01) ◽  
pp. 29-38
Author(s):  
Mira Muhammad ◽  
Angela BM Tulaar ◽  
Rosiana Pradanasari ◽  
Saptawati Bardosono
Keyword(s):  
Plantar Fasciitis ◽  
Walking Speed ◽  
Plantar Fascia ◽  
Term Treatment ◽  
Daily Activities ◽  
Analog Scale ◽  
Short Term ◽  
Short Term Treatment ◽  
Vas Score ◽  
Vas Scores

Plantar fasciitis causes pain in the heel and medial arch of the foot can interfere daily activities. Taping theplantar fasciitis will reduce pain by reducing strain on the plantar fascia during standing and ambulation.Objective: to see the effect of taping on pain and walking speed.Methods: fifteen subjects received taping and ultrasound diathermy therapy for one week. Fifteen othersubjects received ultrasound therapy alone. Pain measured by Visual Analogue Scale (VAS) and the walkingspeed is measured in meters / sec.Results: VAS score started to differ significantly on the first day after treatment (p = 0.008) and continuesuntil the last day of evaluation. On the first day, the VAS score changes differs significantly (p = 0.002). Butin the evaluation of the days, the change of VAS scores were not significantly different. VAS score changes onthe seventh day compared to the initial evaluation found significant (p <0.001). With multivariate analysis ofrepeated measurements, VAS scores in each group decreased significantly (p <0.001), but the decrease in VASscore taping group were significantly better compared with non-taping group (p = 0.004).Conclusion: combination of taping and ultrasound diathermy for people with plantar fasciitis can be used asa modality to reduce pain more quickly.Keywords:plantar fasciitis, taping, ultrasound diathermy, visual analog scale, walking speed.

scholarly journals Combination treatment with valsartan and amlodipine intensifies evening suppression of Bmal1 clock gene in kidneys of spontaneously hypertensive rats

2017 ◽  
Vol 64 (1) ◽  
pp. 22-25
Author(s):  
P. Potucek ◽  
M. Radik ◽  
G. Doka ◽  
E. Kralova ◽  
P. Krenek ◽  
...  
Keyword(s):  
Spontaneously Hypertensive Rats ◽  
Clock Gene ◽  
Term Treatment ◽  
Hypertensive Rats ◽  
Short Term ◽  
Short Term Treatment ◽  
Spontaneously Hypertensive ◽  
Long Term Treatment ◽  
Significant Difference

AbstractBlood pressure (BP) rhythm is exhibited in a circadian pattern regulated by complex system of endogenous factors. Administration of pharmacological treatment at the right time can influence the efficacy of treatment; but while kidneys play significant role in BP regulation, little is known about their role in chronopharmacotherapy. This study aimed to compare differences between morning and evening dosing with valsartan and amlodipine combination in both short-term and long-term settings and to elucidate the role of kidneys in chronopharmacology. Spontaneously hypertensive rats aged between 8 and 10 weeks were daily treated with 10mg/kg of valsartan and 4 mg/kg of amlodipine, either in the morning or in the evening with treatment duration of 1 and 6 weeks. After short-term treatment, only morning treatment group demonstrated significantly better outcomes in terms of BP control when compared to placebo. After long-term treatment, both treatment groups gained superior results in BP control against placebo; however, no significant difference was seen between morning and evening treatment. Interestingly, clock gene expression in kidney has been significantly modulated only in the evening-treated groups, with treatment intensifying the reduced Bmal1 levels, while Per2 expression was less altered. However, no direct relation with the outcomes of the therapy has been observed, suggesting that pharmacotherapy may serve as an independent modulator of peripheral circadian clock in the kidney.

AB0298 LONG-TERM SUPPRESSION OF RAPID RADIOGRAPHIC PROGRESSION AFTER DISCONTINUATION/REDUCTION OF SHORT-TERM BIOLOGIC THERAPY IN PATIENTS WITH EARLY DESTRUCTIVE RHEUMATOID ARTHRITIS ACCOMPANIED WITH EXTENSIVE BONE MARROW EDEMA.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1448-1449
Author(s):  
K. Katayama ◽  
T. Okubo ◽  
T. Sato ◽  
R. Fukai ◽  
M. Yuichi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Marrow ◽  
Biological Treatment ◽  
Bone Marrow Edema ◽  
Radiographic Progression ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Significant Difference ◽  
Marrow Edema

Background:We reported that short-term (3 or 6 months) treatment with biologics (BIO) group compared with conventional synthetic non-biological disease-modifying anti rheumatic drug (csDMARDs) enhanced group is more effective in the reducing bone marrow edema (BE) and improving structural remission in early destructive RA accompanied with extensive hand BM despite csDMARDs therapy (1).Objectives:Purpose of this extended study is to investigate whether suppression of RRP will maintain after the discontinuation/reduction of short term biological treatment during over 1 year. Clinical registration number; (UMIN-CTR 000013614)(Figure 1)Methods:RA disease activity was evaluated by DAS28-ESR after BIO withdrawal/reduction at 12 months. Bone destruction was determined by modified total Sharp scoring (mTSS) using by conventional radiography expressed as yearly progression of mTSS (ΔmTSS/y) at 12 months. Statistical analysis were performed by t-test or Wilcoxon rank sum test using SAS .13.2 softwareResults:Fourteen out of 23 patients in BIO group achieved improvement of BM (>70% improvement of baseline BE). Three patient continued BIO. Among 11 patient started to discontinuation/reduction of BIO, 7 patients were successful for discontinuation of BIO. Four patients flared (Table 1). Mean DAS28-ESR, mean ΔmTSS/y at 0, 12 months after discontinuation in 7 patients were 1.77, 2.02 and -0.66,-0.44, respectively (no significant difference between values in 0 and12 month). In contrast, those in 4 flared patients were 1.91, 4.08 and 0, 1.83, respectively (significant difference). Finally, to resolve baseline prognostic factors for improvement of BE for biological treatment, we compared baseline data between 14 BE improved and 9 BE unimproved RA patients. Low DAS28-ESR at 3 or 6 month (P<0.001) are indicated for significant prognostic factor for improvement of BE, although Low DAS28-ESR at baseline (P=0.07) may associate improvement of BE.Table 1.Summary of 1 year clinical data in 11 patients treated in BIO discontinuation/reduction after improvement of BE by short-term treatment of BIOConclusion:Results of this study indicated suppression of RRP will maintain during over 1 year after the discontinuation of short term biological treatment in some patients. We recommend that a short-term treatment with biologics for early RA patients, who are resistant to non-bio DMARDs therapy and at high risk to transit to RRP, will be an effective and economical treatment strategy.References:[1]K. Katayama, T. Okubo, S. Sato et al. Prevention of extensive bone marrow edema and consequent rapid radiographic progression by short term usage of biologics in DMARDs resistant patients with early destructive rheumatoid arthritis. EULAR meeting. FRI 0124(2018).Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document